Our post-hoc analysis of the NCT00431561 Phase II clinical study outcome data demonstrate that the anti-TGFβ2 RNA therapeutic OT101 exhibits clinically meaningful single-agent activity in the absence of other anti-cancer drugs or radiation therapy and induces durable CR, PR and SD in more than one third of the efficacy population (viz.: 26 of 77 [33.8%]) comprised of R/R HGG patients when intratumorally administered via CED. This evidence concerns the gene TGFB2 and cancer.